EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies

This publication has 186 references indexed in Scilit:

• Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers
  Advanced Science, 2025
• A Neovascularization and EGFR Dual‐Targeting Gold Nanotheranostic System for Non‐Small Cell Lung Cancer Treatment
  Advanced Healthcare Materials, 2025
• Update 2025: Management of Non‑Small-Cell Lung Cancer
  Lung, 2025
• Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single‐plex testing: WJOG13620L
  Cancer Medicine, 2023
• Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12
  Small, 2022
• Editorial for “Preoperative MRI‐Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR‐TKI Treatment in NSCLC”
  Journal of Magnetic Resonance Imaging, 2022
• In vitro and in vivo evaluation of a novel anti-EGFR antibody labeled with 89Zr and 177Lu
  Journal of Radioanalytical and Nuclear Chemistry, 2022
• EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
  Journal of Cancer Research and Clinical Oncology, 2021
• EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
  International Journal of Cancer, 2019
• Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
  JAMA Oncology, 2015